Evidence map›Paper›PMID 17849007›Full record

ArticlePloS one2007

Comparative expression profiling of the Chlamydia trachomatis pmp gene family for clinical and reference strains.

Alexandra Nunes, João P Gomes, Sally Mead, Carlos Florindo, Helena Correia, Maria J Borrego, Deborah Dean

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Molecular pathogenesis ofFrontiers in cellular and infection microbiology · 2023
    Review
  6. Host-Pathogen Interactions ofPathogens (Basel, Switzerland) · 2021
    Article
  7. Transcriptional Expression of theMicroorganisms · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alexandra NunesCenter for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, California, United States of America.
João P Gomes
Sally Mead
Carlos Florindo
Helena Correia
Maria J Borrego
Deborah Dean
University of California, Berkeley · US

Funding

C. trachomatis genomics, strain typing, and evolutionR01AI059647 · NIAID · CHILDREN'S HOSPITAL &RES CTR AT OAKLAND · PI DEAN, DEBORAH ANNE · 2004 to 2008
$2.8M
Pathogenesis of Persistent Chlamydial STDsR01AI039499 · NIAID · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI DEAN, DEBORAH ANNE · 1997 to 2007
$1.3M
NIAID NIH HHS R01 AI039499NIAID NIH HHS R01 AI059647NIAID NIH HHS R01-AI059647NIAID NIH HHS R01-AI39499
6 · The paper itself

Abstract

backgroundChlamydia trachomatis, an obligate intracellular pathogen, is a leading worldwide cause of ocular and urogenital diseases. Advances have been made in our understanding of the nine-member polymorphic membrane protein (Pmp) gene (pmp) family of C. trachomatis. However, there is only limited information on their biologic role, especially for biological variants (biovar) and clinical strains. METHODOLOGY/PRINCIPAL

findingsWe evaluated expression for pmps throughout development for reference strains E/Bour and L2/434, representing different biovars, and for clinical E and L2 strains. Immunoreactivity of patient sera to recombinant (r)Pmps was also determined. All pmps were expressed at two hours. pmpA had the lowest expression but was up-regulated at 12 h for all strains, indicating involvement in reticulate body development. For pmpD, expression peaked at 36 h. Additionally, 57.7% of sera from infected and 0% from uninfected adolescents were reactive to rPmpD (p = 0.001), suggesting a role in immunogenicity. pmpF had the highest expression levels for all clinical strains and L2/434 with differential expression of the pmpFE operon for the same strains. Sera were nonreactive to rPmpF despite immunoreactivity to rMOMP and rPmpD, suggesting that PmpF is not associated with humoral immune responses. pmpFE sequences for clinical strains were identical to those of the respective reference strains. We identified the putative pmpFE promoter, which was, surprisingly, 100% conserved for all strains. Analyses of ribosomal binding sites, RNase E, and hairpin structures suggested complex regulatory mechanism(s) for this >6 Kb operon. CONCLUSIONS/SIGNIFICANCE: The dissimilar expression of the same pmp for different C. trachomatis strains may explain different strain-specific needs and phenotypic distinctions. This is further supported by the differential immunoreactivity to rPmpD and rPmpF of sera from patients infected with different strains. Furthermore, clinical E strains did not correlate with the E reference strain at the gene expression level, reinforcing the need for expansive studies of clinical strains.

Indexed as

Gene Expression ProfilingGenes, BacterialMultigene FamilyBase SequenceChlamydia trachomatisDNA, BacterialDNA PrimersMolecular Sequence DataOperonPolymerase Chain ReactionSequence Homology, Nucleic AcidDNA, BacterialDNA Primers

Identifiers

PMID17849007
PMCPMC1963315
OpenAlexW1970527133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.